Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant

Nicola Gagliani, Tatiana Jofra, Angela Stabilini, Andrea Valle, Mark Atkinson, Maria Grazia Roncarolo, Manuela Battaglia

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - In type 1 diabetes, allogeneic pancreatic islet transplant restores insulin production, but life-threatening immunosuppression is required to avoid graft rejection. Induction of antigen (Ag) - specific tolerance by cell therapy with regulatory. T-cells (Tregs) represents an attractive alternative approach but its therapeutic efficacy in islet transplant remains to be determined. Among the different subsets of CD4+ Tregs, the T inducible regulatory type 1 (Tr1) cells can be generated from naive T-cells in the presence of interleukin-10 (IL-10) and represent one promising therapeutic choice. This study was designed to define the efficacy of Tr1-cell therapy in preclinical models of islet transplant. RESEARCH DESIGN AND METHODS - Non-Ag-specific polyclonal Tr1 cells and donor Ag-specific Tr1 cells were transferred, in the absence of any pharmacological treatment, in two distinct mouse models of islet transplant. The two models differed in their therapeutic stringency, based on the mean rejection time of untreated mice that underwent a transplant. RESULTS - Transfer of polyclonal Tr1 cells engendered graft tolerance only in the nonstringent mouse model. Conversely, cell therapy with Ag-specific Tr1 cells induced an IL-10-dependent tolerance in the stringent mouse model of islet transplant. The therapeutic advantage of Ag-specific Tr1 cells over polyclonal Tr1 cells was due to their donor Ag specificity. CONCLUSIONS - These results demonstrate that Tr1-cell therapy leads to tolerance in settings of islet transplant and that its therapeutic efficacy is highly dependent on the antigen specificity of these cells.

Original languageEnglish
Pages (from-to)433-439
Number of pages7
JournalDiabetes
Volume59
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Regulatory T-Lymphocytes
Cell- and Tissue-Based Therapy
Transplants
Antigens
Interleukin-10
Therapeutics
Transplantation Tolerance
T-Lymphocytes
Graft Rejection
Type 1 Diabetes Mellitus
Islets of Langerhans
Immunosuppression
Research Design
Pharmacology
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Gagliani, N., Jofra, T., Stabilini, A., Valle, A., Atkinson, M., Roncarolo, M. G., & Battaglia, M. (2010). Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes, 59(2), 433-439. https://doi.org/10.2337/db09-1168

Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. / Gagliani, Nicola; Jofra, Tatiana; Stabilini, Angela; Valle, Andrea; Atkinson, Mark; Roncarolo, Maria Grazia; Battaglia, Manuela.

In: Diabetes, Vol. 59, No. 2, 02.2010, p. 433-439.

Research output: Contribution to journalArticle

Gagliani, N, Jofra, T, Stabilini, A, Valle, A, Atkinson, M, Roncarolo, MG & Battaglia, M 2010, 'Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant', Diabetes, vol. 59, no. 2, pp. 433-439. https://doi.org/10.2337/db09-1168
Gagliani N, Jofra T, Stabilini A, Valle A, Atkinson M, Roncarolo MG et al. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes. 2010 Feb;59(2):433-439. https://doi.org/10.2337/db09-1168
Gagliani, Nicola ; Jofra, Tatiana ; Stabilini, Angela ; Valle, Andrea ; Atkinson, Mark ; Roncarolo, Maria Grazia ; Battaglia, Manuela. / Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. In: Diabetes. 2010 ; Vol. 59, No. 2. pp. 433-439.
@article{cc690ddcff8e414280fb4c4bc3dc361d,
title = "Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant",
abstract = "OBJECTIVE - In type 1 diabetes, allogeneic pancreatic islet transplant restores insulin production, but life-threatening immunosuppression is required to avoid graft rejection. Induction of antigen (Ag) - specific tolerance by cell therapy with regulatory. T-cells (Tregs) represents an attractive alternative approach but its therapeutic efficacy in islet transplant remains to be determined. Among the different subsets of CD4+ Tregs, the T inducible regulatory type 1 (Tr1) cells can be generated from naive T-cells in the presence of interleukin-10 (IL-10) and represent one promising therapeutic choice. This study was designed to define the efficacy of Tr1-cell therapy in preclinical models of islet transplant. RESEARCH DESIGN AND METHODS - Non-Ag-specific polyclonal Tr1 cells and donor Ag-specific Tr1 cells were transferred, in the absence of any pharmacological treatment, in two distinct mouse models of islet transplant. The two models differed in their therapeutic stringency, based on the mean rejection time of untreated mice that underwent a transplant. RESULTS - Transfer of polyclonal Tr1 cells engendered graft tolerance only in the nonstringent mouse model. Conversely, cell therapy with Ag-specific Tr1 cells induced an IL-10-dependent tolerance in the stringent mouse model of islet transplant. The therapeutic advantage of Ag-specific Tr1 cells over polyclonal Tr1 cells was due to their donor Ag specificity. CONCLUSIONS - These results demonstrate that Tr1-cell therapy leads to tolerance in settings of islet transplant and that its therapeutic efficacy is highly dependent on the antigen specificity of these cells.",
author = "Nicola Gagliani and Tatiana Jofra and Angela Stabilini and Andrea Valle and Mark Atkinson and Roncarolo, {Maria Grazia} and Manuela Battaglia",
year = "2010",
month = "2",
doi = "10.2337/db09-1168",
language = "English",
volume = "59",
pages = "433--439",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "2",

}

TY - JOUR

T1 - Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant

AU - Gagliani, Nicola

AU - Jofra, Tatiana

AU - Stabilini, Angela

AU - Valle, Andrea

AU - Atkinson, Mark

AU - Roncarolo, Maria Grazia

AU - Battaglia, Manuela

PY - 2010/2

Y1 - 2010/2

N2 - OBJECTIVE - In type 1 diabetes, allogeneic pancreatic islet transplant restores insulin production, but life-threatening immunosuppression is required to avoid graft rejection. Induction of antigen (Ag) - specific tolerance by cell therapy with regulatory. T-cells (Tregs) represents an attractive alternative approach but its therapeutic efficacy in islet transplant remains to be determined. Among the different subsets of CD4+ Tregs, the T inducible regulatory type 1 (Tr1) cells can be generated from naive T-cells in the presence of interleukin-10 (IL-10) and represent one promising therapeutic choice. This study was designed to define the efficacy of Tr1-cell therapy in preclinical models of islet transplant. RESEARCH DESIGN AND METHODS - Non-Ag-specific polyclonal Tr1 cells and donor Ag-specific Tr1 cells were transferred, in the absence of any pharmacological treatment, in two distinct mouse models of islet transplant. The two models differed in their therapeutic stringency, based on the mean rejection time of untreated mice that underwent a transplant. RESULTS - Transfer of polyclonal Tr1 cells engendered graft tolerance only in the nonstringent mouse model. Conversely, cell therapy with Ag-specific Tr1 cells induced an IL-10-dependent tolerance in the stringent mouse model of islet transplant. The therapeutic advantage of Ag-specific Tr1 cells over polyclonal Tr1 cells was due to their donor Ag specificity. CONCLUSIONS - These results demonstrate that Tr1-cell therapy leads to tolerance in settings of islet transplant and that its therapeutic efficacy is highly dependent on the antigen specificity of these cells.

AB - OBJECTIVE - In type 1 diabetes, allogeneic pancreatic islet transplant restores insulin production, but life-threatening immunosuppression is required to avoid graft rejection. Induction of antigen (Ag) - specific tolerance by cell therapy with regulatory. T-cells (Tregs) represents an attractive alternative approach but its therapeutic efficacy in islet transplant remains to be determined. Among the different subsets of CD4+ Tregs, the T inducible regulatory type 1 (Tr1) cells can be generated from naive T-cells in the presence of interleukin-10 (IL-10) and represent one promising therapeutic choice. This study was designed to define the efficacy of Tr1-cell therapy in preclinical models of islet transplant. RESEARCH DESIGN AND METHODS - Non-Ag-specific polyclonal Tr1 cells and donor Ag-specific Tr1 cells were transferred, in the absence of any pharmacological treatment, in two distinct mouse models of islet transplant. The two models differed in their therapeutic stringency, based on the mean rejection time of untreated mice that underwent a transplant. RESULTS - Transfer of polyclonal Tr1 cells engendered graft tolerance only in the nonstringent mouse model. Conversely, cell therapy with Ag-specific Tr1 cells induced an IL-10-dependent tolerance in the stringent mouse model of islet transplant. The therapeutic advantage of Ag-specific Tr1 cells over polyclonal Tr1 cells was due to their donor Ag specificity. CONCLUSIONS - These results demonstrate that Tr1-cell therapy leads to tolerance in settings of islet transplant and that its therapeutic efficacy is highly dependent on the antigen specificity of these cells.

UR - http://www.scopus.com/inward/record.url?scp=77449132554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449132554&partnerID=8YFLogxK

U2 - 10.2337/db09-1168

DO - 10.2337/db09-1168

M3 - Article

C2 - 19934002

AN - SCOPUS:77449132554

VL - 59

SP - 433

EP - 439

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 2

ER -